Devices and methods for treating and closing wounds with negative pressure

Information

  • Patent Grant
  • 11241337
  • Patent Number
    11,241,337
  • Date Filed
    Wednesday, October 31, 2018
    6 years ago
  • Date Issued
    Tuesday, February 8, 2022
    2 years ago
Abstract
The present invention relates to a negative pressure wound closure system and methods for using such a system. Preferred embodiments of the invention facilitate closure of the wound by preferentially contracting to provide for movement of the tissue.
Description
BACKGROUND OF THE INVENTION
Field of the Invention

Embodiments described herein relate to devices and methods that can be used to treat a wound with negative pressure. Particular embodiments can also be useful to aid in wound closure, for example in abdominal wounds.


Description of the Related Art

In the prior art, application of negative pressure may sometimes exert an outward force upon the wound margins due to the atmospheric pressure compressing the wound filler downward and outward against the margins of the wound. This downward compression of the wound filler slows the healing process and slows or prevents wound closure. Accordingly, there is a need to provide for an improved apparatus, method, and system for the treatment and closure of wounds.


SUMMARY OF THE INVENTION

Generally, the embodiments described herein can be used to assist in the treatment of wounds with negative pressure. The embodiments can be particularly useful in treating large wounds, such as abdominal wounds, where closure and approximation of the wound edges is challenging. By limiting the amount of vertical pressure applied to the wound filler, by enhancing the horizontal collapse of the wound filler, and by enhancing attachment of the wound filler to the wound margins, together with additional details described herein, improved wound closure can be obtained.


In some embodiments, a wound filler for use in treating a wound with negative pressure comprises:

    • a porous filling material;
    • a plurality of vertically extending members configured to extend vertically when the wound filler is positioned within a wound bed, the vertically extending members being made of a more rigid material than the porous wound filling material; and
    • wherein upon application of negative pressure to the wound filler, the wound filler is configured to contract horizontally with the vertically extending members reducing vertical movement of the wound filler.


In certain embodiments, the vertically extending members can be struts, slabs, columns or tiles. In some embodiments, the vertically extending members of any of the aforementioned wound filler embodiments are elongate members configured to extend lengthwise across a wound bed and are aligned parallel to one another. In particular embodiments, the porous wound filling material of any of the aforementioned wound filler embodiments can surround the vertically extending members. In some embodiments, the porous wound filling material of any of the aforementioned wound filler embodiments can extend between the vertically extending members. In particular embodiments, the porous wound filling material of any of the aforementioned wound filler embodiments can comprise a plurality of slits or areas in which denser or more rigid struts or slabs are inserted.


In particular embodiments, the wound fillers of any of the aforementioned embodiments can include flexible material positioned between the vertically extending members to allow compression of the vertically extending members towards each other in a horizontal plane when the wound filler is positioned within a wound bed and is placed under negative pressure. In some embodiments, the vertically extending members of any of the aforementioned wound filler embodiments can be adhered to the porous wound filling material.


In some embodiments, one or more draw strings or cords can extend through the wound filler such that pulling of the draw strings causes contraction of the wound filler in a horizontal plane.


In certain embodiments, a negative pressure wound therapy system comprises a wound filler such as those described herein and a wound cover configured to be placed over the wound filler. In certain embodiments, the negative pressure wound therapy system described above further includes a connection for connecting the wound cover to a source of negative pressure. In some embodiments, the aforementioned negative pressure wound therapy system further comprises a negative pressure source configured to be connected to the wound cover to provide negative pressure to the wound filler when placed within the wound bed.


In some embodiments, a method of treating a wound comprises:

    • positioning a wound filler of any one of the previously described embodiments into a wound bed;
    • covering the wound filler with a wound cover; and
    • applying negative pressure to the wound cover, wherein the application of negative pressure causes the wound filler to contract horizontally with the vertically extending members reducing vertical movement of the wound filler.


Other embodiments of wound closure devices, stabilizing structures and associated apparatuses are described below.





BRIEF DESCRIPTION OF THE DRAWINGS

Other features and advantages of the present invention will be apparent from the following detailed description of the invention, taken in conjunction with the accompanying drawings of which:



FIG. 1 illustrates one embodiment of a negative pressure wound therapy system.



FIG. 2A is a cross-sectional view of one embodiment of a wound filler taken through a horizontal plane.



FIG. 2B is a cross-sectional view of a wound with a wound filler positioned therein.



FIG. 2C is a cross-sectional view of another type of wound with a wound filler positioned therein.



FIG. 2D is a cross-sectional view of another type of wound with a wound filler positioned therein.



FIG. 2E is a cross-sectional view of a wound with another embodiment of a wound filler positioned therein.



FIGS. 3A-C illustrate embodiments of wound fillers comprising one or more draw strings.



FIGS. 4A-B illustrate embodiments of a wound filler containing rigid columns or tiles.



FIGS. 5A-22 illustrate further embodiments of the present application.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Embodiments of wound fillers and other wound treatment apparatuses and methods that may be utilized with and/or that may provide further details regarding the embodiments described below are found in U.S. Provisional Application No. 61/651,483, filed May 24, 2012, the entirety of which is hereby incorporated by reference and portions of which are included below in the section titled “Other Negative Pressure Therapy Apparatuses, Dressings, Wound Fillers, and Methods.”


Various embodiments that can be used for the treatment of wounds will now be described with references to the following figures and description which follow. It will be of course understood that various omissions, substitutions, and changes in the form and details of the embodiments illustrated can be made without departing from the spirit of the disclosure. Additionally, the various features and processes described herein can be used independently of one another, or can be combined in various ways. All possible combinations and subcombinations are intended to fall within the scope of this disclosure. Many of the embodiments described herein include similar components, and as such, these similar components can be interchanged in different embodiments.


Embodiments disclosed herein relate to apparatuses and methods of treating a wound with reduced pressure, including pump and wound dressing components and apparatuses. Generally, the embodiments including the wound fillers described herein may be used in combination with a negative pressure system comprising a drape or wound cover placed over the filler. A vacuum source, such as a pump, may be connected to the cover, for example, through one or more tubes connected to an aperture or port made in or under the cover. The apparatuses and components comprising the wound overlay and packing materials, if any, are sometimes collectively referred to herein as dressings. Reference is made to the following applications, which are hereby incorporated by reference in their entireties: U.S. application Ser. No. 12/886,088, titled “SYSTEMS AND METHODS FOR USING NEGATIVE PRESSURE WOUND THERAPY TO MANAGE OPEN ABDOMINAL WOUNDS”, published as US 2011/0213287 on Sep. 1, 2011; and U.S. application Ser. No. 13/092,042, titled “WOUND DRESSING AND METHOD OF USE”, published as US 2011/0282309 on Nov. 17, 2011.


It will be appreciated that throughout this specification reference is made to a wound or wounds. It is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured, or where trauma causes a contusion, or any other superficial or other conditions or imperfections on the skin of a patient or otherwise that benefit from reduced pressure treatment. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, acute wounds, chronic wounds, surgical incisions and other incisions, subacute and dehisced wounds, traumatic wounds, flaps and skin grafts, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like. In some embodiments, the components of the negative pressure treatment system described herein can be particularly suited for incisional wounds that exude a small amount of wound exudate.


As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels that are below standard atmospheric pressure, which corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects absolute pressure that is X mmHg below 760 mmHg or, in other words, an absolute pressure of (760-X) mmHg. In addition, negative pressure that is “less” or “smaller” than X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than −60 mmHg).


The negative pressure range for some embodiments of the present disclosure can be approximately −80 mmHg, or between about −20 mmHg and −200 mmHg. Note that these pressures are relative to normal ambient atmospheric pressure. Thus, −200 mmHg would be about 560 mmHg in practical terms. In some embodiments, the pressure range can be between about −40 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also in other embodiments a pressure range of below −75 mmHg can be used. Alternatively, a pressure range of over approximately −100 mmHg, or even 150 mmHg, can be supplied by the negative pressure apparatus.


As used herein, the term “horizontal.” when referring to a wound, indicates a direction or plane generally parallel to the skin surrounding the wound. The term “vertical,” when referring to a wound, generally refers to a direction extending perpendicular to the horizontal plane. The term “longitudinal,” when referring to a wound, generally refers to a direction in the horizontal plane taken in a direction along which the wound is longest. The term “lateral,” when referring to a wound, generally refers to a direction in the horizontal plane perpendicular to the longitudinal direction. The terms “horizontal,” “vertical,” “longitudinal,” and “lateral” can also be used to describe the wound fillers or other devices described throughout this specification. When describing these wound fillers or devices, these terms should not be construed to require that the structures or devices necessarily be placed into a wound in a certain orientation, though in certain embodiments, it may be preferable to do so.


As used herein, the term “fill material” comprises, in a non-limiting manner: porous wound filler materials and flexible materials. As used herein, compressible materials are included within the scope of flexible materials.


Turning to FIG. 1, treatment of a wound with negative pressure in certain embodiments uses a negative pressure treatment system 101 as illustrated schematically here. In this embodiment, a wound site 110, illustrated here as an abdominal wound site, may benefit from treatment with negative pressure. Such abdominal wound sites may be a result of, for example, an accident or due to surgical intervention. In some cases, medical conditions such as abdominal compartment syndrome, abdominal hypertension, sepsis, or fluid edema may require decompression of the abdomen with a surgical incision through the abdominal wall to expose the peritoneal space, after which the opening may need to be maintained in an open, accessible state until the condition resolves. Other conditions may also necessitate that an opening-particularly in the abdominal cavity—remain open, for example if multiple surgical procedures are required (possibly incidental to trauma), or there is evidence of clinical conditions such as peritonitis or necrotizing fasciitis.


In cases where there is a wound, particularly in the abdomen, management of possible complications relating to the exposure of organs and the peritoneal space is desired, whether or not the wound is to remain open or if it will be closed. Therapy, preferably using the application of negative pressure, can be targeted to minimize the risk of infection, while promoting tissue viability and the removal of deleterious substances from the wound site. The application of reduced or negative pressure to a wound site has been found to generally promote faster healing, increased blood flow, decreased bacterial burden, increased rate of granulation tissue formation, to stimulate the proliferation of fibroblasts, stimulate the proliferation of endothelial cells, close chronic open wounds, inhibit burn penetration, and/or enhance flap and graft attachment, among other things. It has also been reported that wounds that have exhibited positive response to treatment by the application of negative pressure include infected open wounds, decubitus ulcers, dehisced incisions, partial thickness burns, and various lesions to which flaps or grafts have been attached. Consequently, the application of negative pressure to a wound site 110 can be beneficial to a patient.


Accordingly, certain embodiments provide for a wound contact layer 105 to be placed over the wound site 110. Preferably, the wound contact layer 105 can be a thin, flexible material which will not adhere to the wound site or the exposed viscera in close proximity. For example, polymers such as polyurethane, polyethylene, polytetrafluoroethylene, or blends thereof may be used. In one embodiment, the wound contact layer is permeable. For example, the wound contact layer 105 can be provided with openings, such as holes, slits, or channels, to allow the removal of fluids from the wound site 110 or the transmittal of negative pressure to the wound site 110.


Certain embodiments of the negative pressure treatment system 101 may also use a porous wound filler 103, which can be disposed over the wound contact layer 105. This pad 103 can be constructed from a porous material, for example foam, that is soft, resiliently flexible, and generally conformable to the wound site 110. Such a foam can include an open-celled and reticulated foam made, for example, of a polymer. Suitable foams include foams composed of, for example, polyurethane, silicone, and polyvinyl alcohol. Preferably, this pad 103 can channel wound exudate and other fluids through itself when negative pressure is applied to the wound. Some pads 103 may include preformed channels or openings for such purposes. In certain embodiments, the pad 103 may have a thickness between about one inch and about two inches. The pad may also have a length of between about 16 and 17 inches, and a width of between about 11 and 12 inches. In other embodiments, the thickness, width, and/or length can have other suitable values. Other embodiments of wound fillers that may be used in place of or in addition to the pad 103 are discussed in further detail below.


Preferably, a drape 107 is used to seal the wound site 110. The drape 107 can be at least partially liquid impermeable, such that at least a partial negative pressure may be maintained at the wound site. Suitable materials for the drape 107 include, without limitation, synthetic polymeric materials that do not significantly absorb aqueous fluids, including polyolefins such as polyethylene and polypropylene, polyurethanes, polysiloxanes, polyamides, polyesters, and other copolymers and mixtures thereof. The materials used in the drape may be hydrophobic or hydrophilic. Examples of suitable materials include Transeal® available from DeRoyal and OpSite® available from Smith & Nephew. In order to aid patient comfort and avoid skin maceration, the drapes in certain embodiments are at least partly breathable, such that water vapor is able to pass through without remaining trapped under the dressing. An adhesive layer may be provided on at least a portion the underside of the drape 107 to secure the drape to the skin of the patient, although certain embodiments may instead use a separate adhesive or adhesive strip. Optionally, a release layer may be disposed over the adhesive layer to protect it prior to use and to facilitate handling the drape 107; in some embodiments, the release layer may be composed of multiple sections.


The negative pressure system 101 can be connected to a source of negative pressure, for example a pump 114. One example of a suitable pump is the Renasys EZ pump available from Smith & Nephew. The drape 107 may be connected to the source of negative pressure 114 via a conduit 112. The conduit 112 may be connected to a port 113 situated over an aperture 109 in the drape 107, or else the conduit 112 may be connected directly through the aperture 109 without the use of a port. In a further alternative, the conduit may pass underneath the drape and extend from a side of the drape. U.S. Pat. No. 7,524,315 discloses other similar aspects of negative pressure systems and is hereby incorporated by reference in its entirety and should be considered a part of this specification.


In many applications, a container or other storage unit 115 may be interposed between the source of negative pressure 114 and the conduit 112 so as to permit wound exudate and other fluids removed from the wound site to be stored without entering the source of negative pressure. Certain types of negative pressure sources—for example, peristaltic pumps—may also permit a container 115 to be placed after the pump 114. Some embodiments may also use a filter to prevent fluids, aerosols, and other microbial contaminants from leaving the container 115 and/or entering the source of negative pressure 114. Further embodiments may also include a shut-off valve or occluding hydrophobic and/or oleophobic filter in the container to prevent overflow; other embodiments may include sensing means, such as capacitive sensors or other fluid level detectors that act to stop or shut off the source of negative pressure should the level of fluid in the container be nearing capacity. At the pump exhaust, it may also be preferable to provide an odor filter, such as an activated charcoal canister.



FIGS. 2A-2E illustrate embodiments of a wound filler 200 that may be used in the system described above comprising fill material 202 and extending members 204. In some preferred embodiments, the fill material is a porous wound filler material such as described above. In certain preferred embodiments, the fill material 202 is flexible. As shown in a horizontal cross-section in FIG. 2A, the wound filler 200 may include a plurality of extending members 204 contained within an oval-shaped fill material 202. It will be appreciated that the fill material 202 can have other shapes, such as rectangular or square, and that the shape shown in FIG. 2A may simply result from the filler being cut by a health practitioner to an appropriate size. The wound filler as shown in FIG. 2A is shown with an outer dimension sized to fit within an oval-shaped wound when the wound is viewed from above.


In some embodiments, the extending members 204 are denser than the fill material 202. In some embodiments, the extending members 204 are between 1 to 2 times, between 2 to 4 times, between 4 to 6 times, between 6 to 8 times, or 8 times or more dense than the fill material. In certain embodiments, the extending members 204 are more rigid than the fill material 202. In some embodiments, the extending members are between 1 to 2 times, between 2 to 4 times, between 4 to 6 times, between 6 to 8 times, or 8 times or more rigid than the porous wound filling material.


In certain preferable embodiments, and as also shown in FIGS. 2B-2E, the extending members 204 are elongate members that extend vertically when the wound filler 200 is positioned within a wound bed. In particular embodiments, as shown in FIG. 2A, the extending members 204 are elongate members that may also extend horizontally across a portion or the entire longitudinal length of the wound filler when the wound filler 200 is positioned within a wound bed. In some embodiments, the extending members 204 are sheets that may have parallel faces, while in other embodiments, the extending members 204 may comprise struts, slabs, columns, or tiles. In other embodiments, the extending members 204 extend at an angle from the horizontal or vertical plane of the wound.


The extending members 204 may be parallel or substantially parallel to one another, and may be spaced apart 204 either equally or unequally. In horizontal cross-section as shown in FIG. 2A, each of the extending members may have the same thicknesses, or alternatively, they may have different thicknesses. In vertical cross-section as shown in FIGS. 2B-2E, the extending members may have the same vertical height or length, or may have different vertical heights or lengths. The dimensions of the wound filler, and particularly the horizontal length and the vertical height of the extending members as well as the number of extending members, may depend on the size to which the filler material is cut by the health practitioner. In the embodiments shown, the extending members may have a rectangular cross-section in both horizontal and vertical cross-section, where the horizontal length is greater than the thickness, and the vertical height is greater than the thickness. In some embodiments, the extending members may comprise sheets. In one embodiment, the wound filler is configured to be placed in a wound such that the horizontal length of the extending members is parallel or generally parallel to the longitudinal length of the wound, and the thickness dimension of the extending members extend in the lateral direction.


In some embodiments, as shown in FIG. 2A, the fill material 202 contains slits or areas for the insertion of extending members 204. In some embodiments, the extending members 204 can be inserted after the wound filler 200 has been placed in the wound. In other embodiments, the extending members 204 are placed within the wound filler prior to insertion into the wound. In some embodiments, the slits or areas for insertion can be made after the wound filler 200 has been placed in the wound. In certain embodiments, the slits or areas for insertion are made before the wound filler is placed in the wound. In embodiments where the fill material 202 contains slits or areas for insertion of extending members, the slits may be open to a top surface and/or a bottom surface of the fill material to allow the extending members to be vertically inserted. As shown in FIG. 2A, the horizontal length of the extending members may be shorter than a horizontal dimension of the fill material 202, such that the extending members 204 are fully surrounded by the fill material 202 in a horizontal plane. In some embodiments, the extending members may be attached to the fill material, such as with adhesive, barbs, Velcro™ or other attachment mechanisms. In other embodiments, the extending members may simply be inserted into the slits or areas for insertion of the fill material and be connected by friction, an interference fit, a slight expansion of the extending members, or other mechanical forces.


As shown in FIGS. 2B-2D, the extending members can be vertical when positioned within a wound. FIG. 2B illustrates a side or vertical cross-sectional view of an embodiment of a wound filler 200 positioned within a wound 206, with vertical extending members 204 and fill material 202. The extending members may be similar to those shown in FIG. 2A, or they may consist of alternate slabs of material that may be parallel or substantially parallel to one another. Thus, in some embodiments, instead of having extending members inserted or surrounded by fill material, the extending members and fill material can comprise multiple layers, sheets or slabs alternatingly stacked and adhered together to form a hybrid laminate. For example, a layer of more flexible or compressible wound filler (e.g., foam) may alternatingly be stacked with layers of more rigid wound filler. It will be appreciated that even in such a configuration, further layers of porous material such as foam may be placed above and below the wound filler 200, or the entire wound filler may be surrounded by a porous material such as foam.


In some embodiments, upon application of negative pressure to the wound filler 200), for example, using the system previously described with respect to FIG. 1, the wound filler 200 is configured to contract horizontally 208 with the vertical extending members 204 reducing vertical movement of the wound filler 200. The fill material 202 extends between the plurality of vertically extending members 204 and the fill material and the vertically extending members may be adhered together. As shown in FIG. 2B, as negative pressure is applied to close the wound 206, the fill material 202 between the vertically extending members 204 may desirably compress so that the vertically extending members come closer together as the wound closes.



FIG. 2C illustrates a cross-sectional view of an embodiment of a wound filler 200 in a shallow wound 206, comprising a fill material 202 with spaced apart areas in which a plurality of extending members 204 are located. In a similar manner to the embodiments described in FIGS. 2A-2B, the wound filler is configured to compress horizontally 208, but vertical compression is limited.



FIG. 2D illustrates another cross-sectional view of an embodiment of a wound filler 200 for use in a wound 206, similar to the embodiments described in FIGS. 2A-2C, comprising denser material 204 alternating with less dense material 202 similar to the embodiments described above. In the embodiment of FIG. 2D, the wound filler 200 may have or be cut to a shape where the upper and lower surfaces of the wound filler are parallel or substantially parallel. As illustrated, the extending members of denser material 204 may have the same vertical height.



FIG. 2E illustrates an embodiment of a wound filler similar to those described in FIG. 2A-2D, where the wound filler can be placed in an abdominal wound 210 surrounded by abdominal tissue 212. In some embodiments, the wound filler 200 comprises fill material 202 and extending members 204 similar to the embodiments described above. In certain embodiments, when negative pressure is applied, the wound filler 200 is configured to contract in the horizontal plane while remaining rigid in the vertical plane.


In any of the embodiments herein described, the wound filler can be cut to an appropriate shape and size to fit within the wound. The wound filler can be trimmed to shape in any manner, for example by trimming around the circumference of an oval wound filler or by trimming the horizontal edges of a square or rectangular wound filler.


In some embodiments, after the wound filler is appropriately sized, the extending members can be aligned such that, when placed in a wound cavity, they are perpendicular and extend in a vertical direction from the wound bed. In certain embodiments, application of a vacuum can then cause the fill material to contract substantially only in the horizontal plane, as the extending members reduce movement in the vertical direction (and may also resist horizontal movement). In some embodiments, the compression of the filler can aid in closing the wound cavity in the horizontal plane.


In some embodiments, preferably applicable to the embodiments described in FIGS. 2A-2E, the thickness of the extending members can range from 1 to 10 mm (or about 1 to about 10 mm), for example about 1 mm to about 2 mm, about 2 mm to about 3 mm, about 3 mm to about 4 mm, about 4 mm to about 5 mm, about 5 mm to about 6 mm, about 6 mm to about 7 mm, about 7 mm to about 8 mm, about 8 mm to about 9 mm, about 9 mm to about 10 mm, and greater than 10 mm (or greater than about 10 mm). In certain embodiments, the width of the fill material can range from 1 to 20 mm (or about 1 to about 20 mm), for example about 1 mm to about 5 mm, about 5 mm to about 10 mm, about 10 mm to about 15 mm, about 15 mm to about 20 mm, and greater than 20 mm (or greater than about 20 mm). In any of the embodiments described herein, the fill material may be adhered to the extending members. In certain embodiments, the fill material is adhered to the extending members by an adhesive. In certain preferable embodiments, the fill material is adhered to the extending members via Velcro™ tape.


In any of the embodiments described herein, the extending members can be made from rigid plastics such as polystyrene, polycarbonate, poly(meth)acrylates, semi-rigid materials such as silicone, or from rigid foams or felted flexible foams. In some embodiments, felted flexible foams can be made by subjecting flexible foams, e.g. those used as the porous compressible filler, to heat and pressure to produce a dense, semi-rigid foam that is still porous. Such a configuration can also enhance horizontal movement so as to permit greater wound closure.


In some embodiments (not shown but described as FIG. 2 in Provisional Application No. 61/651,483), a wound filler is provided comprising a minimally-compressible central core surrounded by a compressible outer layer. Such a configuration can reduce vertical movement and permit the wound edge to move inward in a direction toward the central core, thereby aiding in closing the wound. Further, the amount of closure can be controlled by varying the size of the central core. In some embodiments, the central core comprises one or more of a rigid foam, closed cell foam, and silicone elastomers or rigid flexible foam. Further embodiments may also comprise alternating concentric rings of more rigid (or more dense) material and less rigid (or less dense) material.


In certain embodiments (not shown but described as FIG. 3 in Provisional Application No. 61/651,483), an embodiment may be configured in the opposite manner as the embodiment described in the paragraph above, with a minimally-compressible outer layer surrounding a compressible core. The minimally-compressible outer layer can be configured to resist vertical compression, while the compression of the central core can aid in wound closure. As with the embodiment of the previous paragraph, this embodiment can be arranged in a concentric circle or oval configuration, or a linear configuration.



FIG. 3A illustrates an embodiment of a wound filler 300 comprising fill material 302 and one or more draw strings or cords 304. The one or more draw strings or cords can extend through the fill material, preferably with free ends extending from the top side of the wound filler (i.e., the side of the filler that will face outward when the wound filler is inserted into a wound). When negative pressure is applied using a system such as described above, the draw strings (which may extend out or under a wound cover) can be tightened, for example by pulling in a vertical direction 306, thereby causing the wound filler to contract substantially only in a horizontal plane.



FIG. 3B illustrates an embodiment of a wound filler 310 comprising fill material 302 and extending members 308 such as described in any of the embodiments above, and one or more draw strings or cords 304. The one or more draw strings or cords extend through the wound filler 310, preferably with free ends extending from the top side of the wound filler. In a preferred embodiment, the fill material 302 and the extending members 308 can be alternating. In a similar manner to the embodiments described in FIGS. 2A-2E, the extending members 308 can be dense, more rigid, or more dense and rigid than the fill material. The one or more draw strings can extend through the wound filler, preferably with free ends extending from the top side of the wound filler (i.e., the side of the filler that will face outward when the wound filler is inserted into a wound).


In the embodiment of FIG. 3B, because the draw strings or cords 304 form loops between adjacent or spaced apart extending members 308, pulling of the draw strings can cause the extending members to compress the fill material therebetween and draw the extending members closer together. In some embodiments, the draw strings can be attached or secured at desired locations to the extending members 308 to facilitate the ability to draw the extending members closer together. In some embodiments, when negative pressure is applied using a system such as described above, the draw strings or cords can be tightened, for example by pulling in a vertical direction 306, thereby causing the wound filler to contract substantially only in a horizontal plane.



FIG. 3C illustrates an embodiment of a wound filler 320 similar to the embodiment described in FIG. 3B, comprising fill material 302, extending members 308, and multiple draw strings 324 configured to cause the wound filler 320 to contract in a horizontal direction. As illustrated, draw strings 324 may be secured to outer extending members 308, and may extend vertically through adjacent extending members out of the wound filler. In certain embodiments, when negative pressure is applied using a system such as described above, the draw strings or cords 324 can be tightened, for example by pulling in a vertical direction 306, thereby causing the wound filler to contract substantially only in a horizontal plane. In certain embodiments, the wound filler contains more than 2, more than 4, more than 6, or more than 8 draw strings or cords. FIGS. 4A-B illustrate different views of embodiments of a wound filler 400 similar to the embodiments described in FIGS. 2A-E. FIG. 4A depicts a horizontal cross-sectional view of a wound filler 400 comprising fill material 402 and extending members 404 extending in a vertical plane or direction. Preferably, the extending members can be rigid columns or tiles. In preferred embodiments, the wound filler will preferentially collapse horizontally when negative pressure is applied, while the rigid columns or tiles 404 substantially prevent the wound filler from collapsing vertically, thus assisting in wound closure. In some preferred embodiments, the wound filler 400 can be cut to the size of the wound, as the columns or tiles 404 are preferably dispersed throughout the wound filler. In a preferred embodiment, the fill material 402 comprises foam. FIG. 4B illustrates a vertical cross section of an embodiment of the wound filler described in FIG. 4A.


In some embodiments, the rigid columns can comprise rigid plastic such as polystyrene, polycarbonate or a semi-rigid material such as a silicone. In certain embodiments, the rigid columns can comprise a rigid or felted foam. In some embodiments, the columns may have a circular cross-section, and may have diameters for example from 5 mm to 10 mm (or about 5 mm to about 10 mm) with a spacing of 5 mm to 10 mm (or about 5 mm to about 10 mm) around them. For example, the diameter of the column can be about 1 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, or greater than 10 mm (or greater than about 10 mm). In certain embodiments, the spacing between the columns can range from about 1 mm to 5 mm, about 5 mm to 10 mm, about 10 mm to 15 mm, about 15 mm to 20 mm, or greater than 20 mm (or greater than about 20 mm).


In some embodiments (not shown but described as FIG. 14 in Provisional Application No. 61/651,483), a wound filler may comprise one or more conduits that extend to the wound-facing perimeter and are configured to communicate negative pressure. Here, once the wound is sealed under a drape, the one or more conduits can apply negative pressure to the wound, thereby contacting one or more areas on the inside perimeter of the wound. The wound filler can comprise fill material and extending members as described hereinbefore. The wound filler is preferably configured to contain one or more laces or filaments with free ends extending in a vertical direction away from the wound. Upon application of negative pressure, and once the edges of the wound have made contact with the wound filler, the one or more laces or filaments can be pulled so as to collapse the wound filler inward, thereby aiding in the closure of the wound. In some embodiments, the laces or filaments are attached to the extending members and may comprise any of the draw string embodiments previously described herein.


In some embodiments, any of the aforementioned wound fillers can comprise a dissolvable foam. In certain embodiments, the wound filler can comprise an area of dissolvable foam surrounding or surrounded by one or more regions of foam that do not dissolve under ordinary physiological conditions. In particular embodiments, the dissolvable foam region can be central and surrounded by one or more strips of non-dissolvable foam. In some embodiments, the dissolvable foam can also be in a ring configuration and surrounded at least on a horizontal plane by non-dissolvable foam (or vice-versa). In certain embodiments, when implanted into a wound, the dissolvable portions of foam can at least partly dissolve, for example upon contact with wound exudate, thereby providing additional space for the non-dissolvable foam to collapse toward. In preferable embodiments, this collapse can be used to promote horizontal closure of the wound. In some embodiments, the dissolvable foam can comprise polyvinyl alcohol foam (PVA).


In certain embodiments, the dissolvable foam can be replaced by a resorbable filler, for example a resorbable tissue filler scaffold. In some embodiments, this tissue filler can be constructed from biodegradable polymers such as polylactic acid, polyglycolic acid, or any combination of the two polymers. In particular embodiments, the resorbable scaffold can be configured to deliver beneficial molecules. In some embodiments, the scaffold is configured to deliver growth factors. In certain embodiments, the scaffold is configured to deliver antimicrobial molecules. In particular embodiments, such a scaffold can be seeded with beneficial cells, such as fibroblasts or stem cells. In some embodiments, such a scaffold can be seeded with keratinocytes.


In some embodiments, any of the aforementioned wound fillers can be constructed from a three-dimensional material comprising stiffer vertical components and compressible components extending in a lateral direction, such as 3D fabrics and fibers. In some embodiments, the material can present itself as a three-dimensional non-woven material. In particular embodiments, such a wound filler material can preferentially collapse or more readily collapse in a horizontal direction while resisting collapse in a vertical direction.


In some embodiments, any of the aforementioned wound filler materials can comprise a foam material with different-sized bubbles. In some embodiments, as smaller bubbles are more resistant to collapse than larger bubbles, the bubble sizes can be tailored to control the contraction of the wound filler. In certain embodiments, bubbles can be arranged in a gradient, such as a lengthwise or circular gradient, to control collapsibility of the wound filler. In certain embodiments, this arrangement of bubbles can be manufactured using a dual dispense injection process, wherein a first material having a first density (e.g., a first pore/bubble/void size) and a second material having a second density (e.g., a second pore/bubble/void size) are injected into a mold or a plurality of molds. In some embodiments, the second material can be the same material as the first material, but have a different pore size or different size voids or bubbles therein. In certain embodiments, foams of different pore, bubble, or void sizes or density can be coupled together.


Some embodiments can comprise foam with varying compressibility obtained by changing the chemistry or makeup of the material used to make the foam as foam is being produced. For example, without limitation, longer soft (more compressible) polymer blocks or plasticizers can be used to make all or a portion of the foam more compressible. In some embodiments, soft (more compressible) blocks or soft (more compressible) portions of the filler can be made from polypropylene glycol or polytetramethylene glycol, or other similar materials. In some embodiments, the filler can have soft (more compressible) blocks or soft (more compressible) portions made from any suitable sufficiently high molecular weight material.


In some embodiments, during manufacture of the foam material, the makeup of the material passing through the injectors or dispensers used to inject or dispense the foam material can be altered such that the density or stiffness of the foam changes along the length of the foam. For example, without limitation, the foam can be manufactured such that softer, more compressible portions are sandwiched or positioned between stiffer, less compressible portions of the same length of foam. Thereby, the foam having varying compressibility can be produced integrally. In certain embodiments, including any of the embodiments herein where the foam or filler can be produced in multiple stages, softer more compressible foam portions can be injected into, or otherwise inserted into voids or bubbles within a less compressible foam material or vice versa, or can be formed (i.e., injected) or positioned between portions of less compressible foam material. In some embodiments, the additional material if formed in separate foam blocks or layers, can be laminated or otherwise coupled with the other material or materials with which it is to be used.


In some embodiments, a method of treating a wound can include positioning any one of the aforementioned wound fillers into a wound bed and covering the wound filler with a wound cover. Applying negative pressure to such an embodiment can cause the wound filler to contract horizontally with the vertically extending members reducing vertical movement of the wound filler.


Other Negative Pressure Therapy Apparatuses, Dressings, Wound Fillers, and Methods


Further embodiments of negative pressure therapy apparatuses, dressings, wound fillers and methods of using the same that may be utilized alone or in combination with the embodiments described herein, and further description of the embodiments found above, are found in U.S. Provisional Application No. 61/651,483, filed May 24, 2012, the entirety of which is hereby incorporated by reference. Portions of U.S. Provisional Application No. 61/651,483, which was included as an Appendix in U.S. Provisional Application No. 61/782,270, are reproduced below.



FIGS. 5A-5C illustrate embodiments of a porous wound filling material with slits or areas in which a denser porous wound filling material has been inserted, similar to the embodiments disclosed in FIGS. 2A-E. The embodiment is configured to be inserted into a wound. In some embodiments, the porous wound filling material is foam, for example an open-cell foam. The aforementioned embodiments can also enhance horizontal movement so as to permit greater wound closure.


In a manner similar to the embodiment disclosed in FIG. 2B, FIG. 5B illustrates an embodiment of a wound filler material that can be cut to shape and can consist of alternate slabs of flexible or compressible wound filler (e.g., foam) together with more rigid wound filler. FIG. 6 illustrates a wound filler comprising a minimally-compressible central core surrounded by a compressible outer layer. Such a configuration can reduce vertical movement and permit the wound edge to move inward in a direction toward the central core, thereby aiding in closing the wound. Further, the amount of closure can be controlled by varying the size of the central core. In some embodiments, the central core comprises one or more of a rigid foam, closed cell foam, and silicone elastomers.



FIG. 7 illustrates an embodiment that is configured in the opposite manner as FIG. 6 above, with a minimally-compressible outer layer surrounding a compressible core. The minimally-compressible outer layer can be configured to resist vertical compression, while the compression of the central core can aid in wound closure. As with FIG. 6, FIG. 7 can be arranged in a concentric circle or oval configuration, or a linear configuration.


In this embodiment, the treatment device comprises a wound filler (e.g., foam) with telescopic tubes. The wound filler can be placed into a wound cavity with telescopic tubes positioned across the major axis of the wound and on top of the filler and periwound area. In other embodiments, the tubes can be integrated through the wound filler. A drape can then be placed over the treatment device, and the entire assembly fluidically attached to a source of negative pressure.


Application of negative pressure will cause the filler to collapse in a horizontal plane, but the tubes will reduce vertical movement of the filler (which would otherwise apply a horizontal force that makes wound closure more difficult). As the wound margins contract, the telescopic tubes will collapse along their length, thus closing together with the wound.


With reference to FIG. 9, in this embodiment, wound filling material such as foam is placed into a wound cavity. One or more stiffeners can then be placed over the wound, wound filler, and periwound area. The one or more stiffeners can be constructed from a rigid or semi-rigid material (such as a closed-cell foam) that resists compression. Application of a vacuum causes the foam to collapse in the horizontal plane, while the one or more stiffeners reduce vertical compression of the foam.



FIG. 10 illustrates an embodiment of a wound filler with a minimally-adherent wound contact layer on its base and configured to be placed in contact with the wound bed. In some embodiments, the wound contact layer can comprise silicone, or a foam with a thicker skin on one side. When vacuum is applied, the minimally-adherent wound contact layer would promote horizontal contraction of the foam so as to permit greater wound closure. Any of the embodiments disclosed herein, including without limitation those having foam or other fillers or wound packing, those having columns or struts or other support elements, can have a silicone or other slick material or film on one or more wound contacting surfaces thereof to reduce the adhesion or stickiness with respect to the wound.



FIG. 11 illustrates an embodiment where a wound filler, which can be constructed from foam, comprises one or more threads or wires inserted therein. The wires preferably extend in a horizontal plane, and can be constructed from a shape-memory polymer or metal. The wires are preferably inserted or cast into the wound filler in an extended shape, and upon application of a stimulus, the wound filler preferentially contracts in the horizontal plane. In some embodiments, the stimulus causing contraction of the thread or wire can be moisture, heat, or application of reduced pressure.


In some embodiments, the wound filler can comprise entirely or in part an elastomeric shape-memory foam. The shape-memory foam can be pre-stressed into an extended configuration, and, upon exposure to moisture, will contract. An example of a suitable shape-memory foam is Elast-Eon™.


In this embodiment, a wound filler has one or more draw strings or cords extending through it, preferably with free ends extending from the top side of the wound filler (i.e., the side of the filler that will face outward when the wound filler is inserted into a wound). When negative pressure is applied, the draw strings can be tightened, for example by pulling in a vertical direction, thereby causing the foam to contract substantially only in a horizontal plane.



FIG. 12 illustrates an embodiment similar to the embodiment described in FIG. 3A-C. Draw strings or cords may extend through the structure. The drawstrings tighten under negative pressure and cause the structure to contract in only one plane.



FIG. 13 illustrates an embodiment with a wound filler material with rigid columns or tiles extending in a vertical plane or direction, an embodiment similar to the embodiments described in FIGS. 4A-B. The wound filler, which can comprise foam, will preferentially collapse horizontally when negative pressure is applied. The rigid columns or tiles will substantially prevent the wound filler from collapsing vertically, thus assisting in wound closure. Advantageously, the wound filler can be cut to the size of the wound, as the columns or tiles are preferably dispersed throughout the wound filler.



FIG. 14 illustrates an embodiment of a wound closure device comprising a rigid oasis, or core, surrounded by a soft, conformable wound filler such as a reticulated foam. The core comprises one or more passages communicating between the filler material and a source of negative pressure. Upon application of negative pressure, the wound filler will collapse toward the core, thereby preferentially collapsing in a horizontal plane and facilitating wound closure. In one embodiment, the core comprises a central conduit configured to be connected to the source of negative pressure (e.g., via a conduit or a miniature pump), where the central conduit links to one or more peripheral conduits in fluidic communication with the filler.



FIG. 15 illustrates an embodiment of a wound closure system comprising a wound filler placed inside a wound and overlaid with a drape and frame. The frame can be placed or assembled over the foam and onto the periwound area outside of the drape, and attaches to the drape so as to restrict vertical movement of the drape and wound filler. Accordingly, horizontal collapse of the filler will be maximized.


With reference to FIG. 16A, this embodiment can have an inflatable bladder surrounded at least in part by a porous wound filler material such as foam. The inflatable bladder can be filled with liquid, and preferably comprises one or more ports (e.g., a syringe port) that can be used to adjust the amount of fluid therein. In use, the device is placed into a wound and covered with a drape, and, upon application of negative pressure, fluid can be withdrawn from the inflatable bladder to control the amount of contraction of the wound margins. Preferably, the fluid is withdrawn via a tube connected through or under the drape that connects the port to a different source of negative pressure such as a syringe.


In a manner similar to the embodiment illustrated in FIG. 16A, FIG. 16B illustrates an embodiment with an inflatable bag surrounded at least in part by a wound filler such as foam. Here, the inflatable bag is filled with air or gas, and suction (separate from a source of negative pressure used to treat the wound) can be applied to control the amount of contraction of the foam.



FIG. 17 illustrates a semi-rigid wound filler comprising one or more conduits extending to a wound-facing perimeter of the filler that are configured to communicate negative pressure. Here, once the wound is sealed under a drape, the one or more conduits apply negative pressure to the wound, thereby contacting one or more areas on the inside perimeter of the wound. The semi-rigid wound filler is preferably configured to contain one or more laces or filaments with free ends extending in a vertical direction away from the wound. Upon application of negative pressure, and once the edges of the wound have made contact with the wound filler, the laces can be pulled so as to collapse the wound filler, thereby aiding in the closure of the wound.


In FIG. 18, an embodiment of a wound filler such as foam can have its outside (wound-facing) edges cut to provide additional surface area and protrusions to aid in fixation to the wound surface. These edges can consequently enhance wound closure by aiding in pulling the wound edges together upon the application of negative pressure. For example, pinking shears or other serrated cutting implements can be used to add a sawtoothed, wavy, corrugated, irregular, or roughened outer perimeter to the wound filler. Other embodiments can provide for grit-blasting, sanding, or adding particulates to the surface of the wound filler.



FIG. 19 illustrates an embodiment of a pressure responsive foam for use in a wound. Upon application of negative pressure, conventional foams tend to collapse to approximately the same dimensions over the therapeutic ranges of negative pressure applied thereto. However, by tailoring a pressure responsive foam where the volume changes across the therapeutic range of negative pressure, greater control over wound closure can be achieved. For example, such a foam can have a given volume V1 at a given pressure P1. If the negative pressure is increased to a new pressure P2, the foam's volume can decrease to a new volume V2 that is smaller than V1. Accordingly, wound closure can be controlled by application of negative pressure to the wound.



FIG. 20 illustrates an embodiment of a wound filler comprising a dissolvable foam. Here, the wound filler can comprise an area of dissolvable foam surrounding or surrounded by one or more regions of foam that do not dissolve under ordinary physiological conditions. In some configurations, the dissolvable foam region can be central and surrounded by one or more strips of non-dissolvable foam. The dissolvable foam can also be in a ring configuration and surrounded at least on a horizontal plane by non-dissolvable foam (or vice-versa). When implanted into a wound, the dissolvable portions of foam would at least partly dissolve, for example upon contact with wound exudate, thereby providing additional space for the non-dissolvable foam to collapse toward. This can be used to promote horizontal closure of the wound. In some embodiments, the dissolvable foam can comprise polyvinyl alcohol foam (PVA). In some embodiments, the dissolvable foam can be replaced by a resorbable filler, for example a resorbable tissue filler scaffold. In some embodiments, such a scaffold can be seeded with beneficial cells, such as fibroblasts or stem cells.



FIG. 21 illustrates an embodiment of a wound closure device comprising a camera-shutter or iris-like configuration of multiple pieces of wound filler material. Preferably, the wound filler material is substantially rigid at least in a vertical plane. The multiple pieces of wound filler material are preferably configured to move inward from an open configuration illustrated above to a closed configuration upon the application of negative pressure, thereby contracting the wound margins in a horizontal plane. The inward movement of the multiple pieces of wound filler material may resemble the inward movement of a camera shutter.



FIG. 22 illustrates an embodiment of a wound filler device comprising one or more hooks disposed on an outer perimeter thereof, and preferably along a horizontal outer perimeter. The one or more hooks are configured to engage the edges of a wound so as to aid attachment of the filler, thereby aiding in wound closure upon the application of negative pressure. The one or more hooks can be made by using a sudden localized “blast” of heat that can partly melt the foam edge so as to produce a spike, hook, or other protrusion. Application of electrostatic energy to the wound filler can also be used to make the one or more hooks.


Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.


While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated and/or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure.


Although the present disclosure includes certain embodiments, examples and applications, it will be understood by those skilled in the art that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof including embodiments which do not provide all of the features and advantages set forth herein. Accordingly, the scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments herein, and may be defined by claims as presented herein or as presented in the future.

Claims
  • 1. A wound filler for use in treating a wound with negative pressure, comprising: a porous wound filling material that contracts in a horizontal plane of a wound upon application of negative pressure to the wound, the porous wound filling material extending in lateral and longitudinal directions within the horizontal plane;a wound cover that extends over the wound, the wound cover being configured to connect to a negative pressure source to apply negative pressure to the wound; anda contraction device controlled by a user to reduce a size of the wound filling material in the lateral direction including one or more draw strings or cords extending through the porous wound filling material and configured to extend out of or under the wound cover such that pulling of the draw strings or cords further contracts the wound filling material in the lateral direction within the horizontal plane.
  • 2. The wound filler of claim 1 wherein the porous wound filling material preferentially contracts in the lateral direction relative to the longitudinal direction within the wound.
  • 3. The wound filler of claim 1 wherein the porous wound filling material further comprises an open cell foam having an oval shape.
  • 4. The wound filler of claim 1 wherein the porous wound filling material further comprises members that extend within portions of the porous wound filling material.
  • 5. The wound filler of claim 1 wherein the porous wound filling material further comprises a plurality of vertically extending members within the porous wound filling material, the vertically extending members being translated in the lateral direction over a wound contact layer positioned under the porous wound filling material within the wound.
  • 6. The wound filler of claim 5 wherein the vertically extending members are spaced apart between portions of foam within the porous wound filling material.
  • 7. A device for negative pressure wound therapy comprising: a porous wound filling material that contracts in a horizontal plane of a wound upon application of negative pressure to the wound that extends in a longitudinal direction in a skin surface of a patient wherein the horizontal plane has lateral and longitudinal axes;a wound cover that extends over the wound and is configured to be connected to a negative pressure source to apply negative pressure to the wound; anda contraction device controllable by a user to reduce a size of the wound filling material, the contraction device positioned at least partially outside the wound cover and configured to apply a lateral force to the porous wound filling material within the wound cover that contracts in a lateral direction within the horizontal plane.
  • 8. The device of claim 7 wherein the contraction device comprises a bag within the wound filling material, the hag being controllably suctioned to cause the wound to contract horizontally.
  • 9. The device of claim 7 wherein the contraction device comprises a frame that extends over a periwound area.
  • 10. The device of claim 7 wherein the contraction device comprises cords or strings that extend through the wound filling material that are pulled by a user to cause preferential contraction of the wound in a lateral direction relative to a longitudinal direction.
  • 11. The device of claim 10 wherein the cords or strings engage vertically extending elements within the wound filling material, the cords or strings being pulled to reduce the spacing between the vertically extending elements.
  • 12. The device of claim 7 wherein the contraction device comprises horizontal elements that contract laterally with the wound filling material.
  • 13. The device of claim 10 wherein the wound cover comprises a drape extending over the wound such that, the cords or strings pass through the drape.
  • 14. The device of claim 7 wherein the wound filling material includes vertical elements.
  • 15. The device of claim 14 wherein the vertical elements are spaced apart within a compressible foam.
  • 16. The device of claim 7 wherein the wound filling material has an oval shape.
  • 17. A device for negative pressure wound therapy comprising: a porous wound filling material that contracts in a horizontal plane of a wound upon application of negative pressure to the wound that extends in a longitudinal direction in a skin surface of a patient wherein the horizontal plane has lateral and longitudinal axes;a plurality of vertically extending elements within the wound filling material to reduce vertical movement of the wound filling material;a wound cover that extends over the wound and configured to be connected to a negative pressure source to apply negative pressure to the wound; anda contraction device controllable by a user to reduce a size of the wound filling material, the contraction device positioned at least partially outside the wound cover and configured to apply a lateral force to the porous wound filling material within the wound cover that contracts in a lateral direction within the horizontal plane.
  • 18. The device of claim 17 further comprising a negative pressure source coupled to the wound cover.
  • 19. The device of claim 17 wherein the wound filling material comprises foam and the vertically extending elements comprise rigid foam or plastic members.
  • 20. The device of claim 17 wherein the contraction device comprises strings or cords that extend at least partially around the vertically extending elements.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser. No. 14/403,163, filed Nov. 21, 2014, which is a national stage application of International Patent Application No. PCT/IB2013/001555, filed on May 23, 2013, which claims the benefit of U.S. Provisional Application Nos. 61/651,483, filed May 24, 2012, entitled DEVICES AND METHODS FOR TREATING AND CLOSING WOUNDS WITH NEGATIVE PRESSURE, and 61/782,270, filed Mar. 14, 2013, entitled DEVICES AND METHODS FOR TREATING AND CLOSING WOUNDS WITH NEGATIVE PRESSURE, the contents of which are hereby incorporated by reference in their entireties as if fully set forth herein. The benefit of priority to the foregoing applications is claimed under the appropriate legal basis including, without limitation, under 35 U.S.C. § 119(e).

US Referenced Citations (566)
Number Name Date Kind
1006716 Bloomer Oct 1911 A
3014483 Frank et al. Dec 1961 A
3194239 Sullivan Jul 1965 A
3578003 Everett May 1971 A
3789851 Leveen Feb 1974 A
3812616 Koziol May 1974 A
3952633 Nakai Apr 1976 A
4000845 Zeller Jan 1977 A
4467805 Fukuda Aug 1984 A
4608041 Nielsen Aug 1986 A
4637819 Ouellette et al. Jan 1987 A
4699134 Samuelsen Oct 1987 A
4771482 Shlenker Sep 1988 A
4815468 Annand Mar 1989 A
5176663 Svedman et al. Jan 1993 A
5264218 Rogozinski Nov 1993 A
5332149 Gepfer Jul 1994 A
5368910 Langdon Nov 1994 A
5368930 Samples Nov 1994 A
5376067 Daneshvar Dec 1994 A
5409472 Rawlings et al. Apr 1995 A
5415715 Delage et al. May 1995 A
5423857 Rosenman et al. Jun 1995 A
5512041 Bogart Apr 1996 A
5514105 Goodman, Jr. et al. May 1996 A
5562107 Lavender et al. Oct 1996 A
5584859 Brotz Dec 1996 A
5636643 Argenta et al. Jun 1997 A
5695777 Donovan et al. Dec 1997 A
5853863 Kim Dec 1998 A
5928210 Ouellette et al. Jul 1999 A
5960497 Castellino et al. Oct 1999 A
6000403 Cantwell Dec 1999 A
6080168 Levin et al. Jun 2000 A
6086591 Bojarski Jul 2000 A
6142982 Hunt et al. Nov 2000 A
6176868 Detour Jan 2001 B1
6291050 Cree et al. Sep 2001 B1
6398767 Fleischmann Jun 2002 B1
6471715 Weiss Oct 2002 B1
6500112 Khouri Dec 2002 B1
6503208 Skovlund Jan 2003 B1
6530941 Muller et al. Mar 2003 B1
6548727 Swenson Apr 2003 B1
6553998 Heaton et al. Apr 2003 B2
6566575 Stickels et al. May 2003 B1
6641575 Lonky Nov 2003 B1
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6712830 Esplin Mar 2004 B2
6712839 Lonne Mar 2004 B1
6767334 Randolph Jul 2004 B1
6770794 Fleischmann Aug 2004 B2
6776769 Smith Aug 2004 B2
6787682 Gilman Sep 2004 B2
6814079 Heaton et al. Nov 2004 B2
6883531 Perttu Apr 2005 B1
6893452 Jacobs May 2005 B2
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
6977323 Swenson Dec 2005 B1
6994702 Johnson Feb 2006 B1
7004915 Boynton et al. Feb 2006 B2
7025755 Epstein et al. Apr 2006 B2
7070584 Johnson et al. Jul 2006 B2
7117869 Heaton et al. Oct 2006 B2
7128735 Weston et al. Oct 2006 B2
7144390 Hannigan et al. Dec 2006 B1
7153312 Torrie et al. Dec 2006 B1
7156862 Jacobs et al. Jan 2007 B2
7172615 Morriss et al. Feb 2007 B2
7189238 Lombardo et al. Mar 2007 B2
7196054 Drohan et al. Mar 2007 B1
7198046 Argenta et al. Apr 2007 B1
7216651 Argenta et al. May 2007 B2
D544092 Lewis Jun 2007 S
7262174 Jiang et al. Aug 2007 B2
7279612 Heaton et al. Oct 2007 B1
7315183 Hinterscher Jan 2008 B2
7351250 Zamierowski Apr 2008 B2
7361184 Joshi Apr 2008 B2
7367342 Butler May 2008 B2
7381211 Zamierowski Jun 2008 B2
7381859 Hunt et al. Jun 2008 B2
7413571 Zamierowski Aug 2008 B2
7438705 Karpowicz et al. Oct 2008 B2
7494482 Orgill et al. Feb 2009 B2
7524315 Blott et al. Apr 2009 B2
7534240 Johnson May 2009 B1
7540848 Hannigan et al. Jun 2009 B2
7553306 Hunt et al. Jun 2009 B1
7553923 Williams et al. Jun 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7578532 Schiebler Aug 2009 B2
D602583 Pidgeon et al. Oct 2009 S
7611500 Lina et al. Nov 2009 B1
7612248 Burton et al. Nov 2009 B2
7615036 Joshi et al. Nov 2009 B2
7617762 Ragner Nov 2009 B1
7618382 Vogel et al. Nov 2009 B2
7622629 Aali Nov 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7645269 Zamierowski Jan 2010 B2
7651484 Heaton et al. Jan 2010 B2
7670323 Hunt et al. Mar 2010 B2
7678102 Heaton Mar 2010 B1
7683667 Kim et al. Mar 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7699830 Martin et al. Apr 2010 B2
7699831 Bengtson et al. Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston et al. May 2010 B2
7713743 Villanueva et al. May 2010 B2
7722528 Arnal et al. May 2010 B2
7723560 Lockwood et al. May 2010 B2
7753894 Blott et al. Jul 2010 B2
7754937 Boehringer et al. Jul 2010 B2
7776028 Miller et al. Aug 2010 B2
7777522 Yang et al. Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
D625801 Pidgeon et al. Oct 2010 S
7811269 Boynton et al. Oct 2010 B2
7815616 Boehringer et al. Oct 2010 B2
7820453 Heylen et al. Oct 2010 B2
7846141 Weston Dec 2010 B2
7857806 Karpowicz et al. Dec 2010 B2
7863495 Aali Jan 2011 B2
7892181 Christensen et al. Feb 2011 B2
7896856 Petrosenko et al. Mar 2011 B2
7909805 Weston et al. Mar 2011 B2
7910789 Sinyagin Mar 2011 B2
7931774 Hall et al. Apr 2011 B2
7942866 Radl et al. May 2011 B2
7951124 Boehringer et al. May 2011 B2
7964766 Blott et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
7976524 Kudo et al. Jul 2011 B2
7981098 Boehringer et al. Jul 2011 B2
8030534 Radl et al. Oct 2011 B2
8057447 Olson et al. Nov 2011 B2
8062272 Weston et al. Nov 2011 B2
8062295 McDevitt et al. Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8067662 Aali et al. Nov 2011 B2
8070773 Zamierowski Dec 2011 B2
8080702 Blott et al. Dec 2011 B2
8100887 Weston et al. Jan 2012 B2
8114126 Heaton et al. Feb 2012 B2
8123781 Zamierowski Feb 2012 B2
8128615 Blott et al. Mar 2012 B2
8129580 Wilkes et al. Mar 2012 B2
8142419 Heaton et al. Mar 2012 B2
8162909 Blott et al. Apr 2012 B2
8172816 Kazala, Jr. et al. May 2012 B2
8182413 Browning May 2012 B2
8187237 Seegert May 2012 B2
8188331 Barta et al. May 2012 B2
8192409 Hardman et al. Jun 2012 B2
8197467 Heaton et al. Jun 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8215929 Shen et al. Jul 2012 B2
8235955 Blott et al. Aug 2012 B2
8235972 Adahan Aug 2012 B2
8246590 Hu et al. Aug 2012 B2
8246606 Stevenson et al. Aug 2012 B2
8246607 Karpowicz et al. Aug 2012 B2
8257328 Augustine et al. Sep 2012 B2
8273105 Cohen et al. Sep 2012 B2
8298200 Vess et al. Oct 2012 B2
8328776 Kelch et al. Dec 2012 B2
8337411 Nishtala et al. Dec 2012 B2
8353931 Stopek et al. Jan 2013 B2
8357131 Olson Jan 2013 B2
8362315 Aali Jan 2013 B2
8376972 Fleischmann Feb 2013 B2
8399730 Kazala, Jr. et al. Mar 2013 B2
8430867 Robinson et al. Apr 2013 B2
8439882 Kelch May 2013 B2
8444392 Turner et al. May 2013 B2
8444611 Wilkes et al. May 2013 B2
8447375 Shuler May 2013 B2
8454990 Canada et al. Jun 2013 B2
8460255 Joshi et al. Jun 2013 B2
8460257 Locke et al. Jun 2013 B2
8481804 Timothy Jul 2013 B2
8486032 Seegert et al. Jul 2013 B2
8500704 Boehringer et al. Aug 2013 B2
8500776 Ebner Aug 2013 B2
8523832 Seegert Sep 2013 B2
8535296 Blott et al. Sep 2013 B2
8562576 Hu et al. Oct 2013 B2
8608776 Coward et al. Dec 2013 B2
8622981 Hartwell et al. Jan 2014 B2
8628505 Weston Jan 2014 B2
8632523 Eriksson et al. Jan 2014 B2
8673992 Eckstein et al. Mar 2014 B2
8679080 Kazala, Jr. et al. Mar 2014 B2
8679153 Dennis Mar 2014 B2
8680360 Greener et al. Mar 2014 B2
8708984 Robinson et al. Apr 2014 B2
8715256 Greener May 2014 B2
8721629 Hardman et al. May 2014 B2
8746662 Poppe Jun 2014 B2
8747375 Barta et al. Jun 2014 B2
8764732 Hartwell Jul 2014 B2
8784392 Vess et al. Jul 2014 B2
8791315 Lattimore et al. Jul 2014 B2
8791316 Greener Jul 2014 B2
8801685 Armstrong et al. Aug 2014 B2
8802916 Edward et al. Aug 2014 B2
8814842 Coulthard et al. Aug 2014 B2
8821535 Greener Sep 2014 B2
8843327 Vernon-Harcourt et al. Sep 2014 B2
8853486 Wild et al. Oct 2014 B2
8882730 Zimnitsky et al. Nov 2014 B2
8936618 Sealy et al. Jan 2015 B2
8945030 Weston et al. Feb 2015 B2
8951235 Allen et al. Feb 2015 B2
8956336 Haggstrom et al. Feb 2015 B2
9044579 Blott et al. Jun 2015 B2
9050398 Armstrong et al. Jun 2015 B2
9061095 Adie et al. Jun 2015 B2
9084845 Adie et al. Jul 2015 B2
9180132 Fein et al. Nov 2015 B2
9180231 Greener Nov 2015 B2
9204801 Locke et al. Dec 2015 B2
9220822 Hartwell Dec 2015 B2
9226737 Dunn Jan 2016 B2
9301742 Dunn Apr 2016 B2
9339248 Tout et al. May 2016 B2
9352076 Boynton et al. May 2016 B2
9408755 Larsson et al. Aug 2016 B2
9421132 Dunn et al. Aug 2016 B2
9555170 Fleischmann Jan 2017 B2
9597484 Dunn Mar 2017 B2
9655807 Locke et al. May 2017 B2
9737649 Begin et al. Aug 2017 B2
9757500 Locke et al. Sep 2017 B2
9770368 Robinson et al. Sep 2017 B2
9801986 Greener Oct 2017 B2
9820888 Greener et al. Nov 2017 B2
D805039 Dejanovic et al. Dec 2017 S
9844472 Hammond et al. Dec 2017 B2
9849023 Hall et al. Dec 2017 B2
9895270 Coward et al. Feb 2018 B2
9962295 Dunn et al. May 2018 B2
10070994 Dodd et al. Sep 2018 B2
10117782 Dagger et al. Nov 2018 B2
10124098 Dunn et al. Nov 2018 B2
10130520 Dunn et al. Nov 2018 B2
10143485 Locke et al. Dec 2018 B2
10179073 Hartwell et al. Jan 2019 B2
10201642 Hartwell et al. Feb 2019 B2
10245185 Hicks et al. Apr 2019 B2
10405861 Dunn Sep 2019 B2
10537657 Phillips et al. Jan 2020 B2
10575991 Dunn Mar 2020 B2
10660992 Canner et al. May 2020 B2
10814049 Dunn Oct 2020 B2
11083631 Dunn et al. Aug 2021 B2
20010029956 Argenta et al. Oct 2001 A1
20010034499 Sessions et al. Oct 2001 A1
20020022861 Jacobs et al. Feb 2002 A1
20020077661 Saadat Jun 2002 A1
20020161346 Lockwood et al. Oct 2002 A1
20030108587 Orgill et al. Jun 2003 A1
20030114816 Underhill et al. Jun 2003 A1
20030114818 Benecke et al. Jun 2003 A1
20030114821 Underhill et al. Jun 2003 A1
20030120249 Wulz et al. Jun 2003 A1
20030121588 Pargass et al. Jul 2003 A1
20030178274 Chi Sep 2003 A1
20030220660 Kortenbach et al. Nov 2003 A1
20040006319 Lina et al. Jan 2004 A1
20040010275 Jacobs et al. Jan 2004 A1
20040030304 Hunt et al. Feb 2004 A1
20040054346 Zhu et al. Mar 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040147465 Jiang et al. Jul 2004 A1
20040162512 Liedtke et al. Aug 2004 A1
20040243073 Lockwood et al. Dec 2004 A1
20040267312 Kanner et al. Dec 2004 A1
20050107731 Sessions May 2005 A1
20050119694 Jacobs et al. Jun 2005 A1
20050131414 Chana Jun 2005 A1
20050142331 Anderson et al. Jun 2005 A1
20050182445 Zamierowski Aug 2005 A1
20050209574 Boehringer et al. Sep 2005 A1
20050222544 Weston Oct 2005 A1
20050222613 Ryan Oct 2005 A1
20050240220 Zamierowski Oct 2005 A1
20050258887 Ito et al. Nov 2005 A1
20050267424 Eriksson et al. Dec 2005 A1
20060020269 Cheng Jan 2006 A1
20060058842 Wilke et al. Mar 2006 A1
20060064124 Zhu et al. Mar 2006 A1
20060069357 Marasco Mar 2006 A1
20060079599 Arthur et al. Apr 2006 A1
20060135921 Wiercinski et al. Jun 2006 A1
20060213527 Argenta et al. Sep 2006 A1
20060217795 Besselink et al. Sep 2006 A1
20060257457 Gorman et al. Nov 2006 A1
20060259074 Kelleher et al. Nov 2006 A1
20060271018 Korf Nov 2006 A1
20070027414 Hoffman et al. Feb 2007 A1
20070027475 Pagedas Feb 2007 A1
20070032755 Walsh Feb 2007 A1
20070032763 Vogel Feb 2007 A1
20070038172 Zamierowski Feb 2007 A1
20070052144 Knirck et al. Mar 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070104941 Kameda et al. May 2007 A1
20070118096 Smith et al. May 2007 A1
20070123816 Zhu et al. May 2007 A1
20070123973 Roth et al. May 2007 A1
20070129660 McLeod et al. Jun 2007 A1
20070149910 Zocher Jun 2007 A1
20070161937 Aali Jul 2007 A1
20070179421 Farrow Aug 2007 A1
20070185463 Mulligan Aug 2007 A1
20070213597 Wooster Sep 2007 A1
20070219513 Lina et al. Sep 2007 A1
20070265585 Joshi et al. Nov 2007 A1
20070282309 Bengtson et al. Dec 2007 A1
20070282374 Sogard et al. Dec 2007 A1
20070299541 Chernomorsky et al. Dec 2007 A1
20080041401 Casola et al. Feb 2008 A1
20080103462 Wenzel et al. May 2008 A1
20080108977 Heaton et al. May 2008 A1
20080167593 Fleischmann Jul 2008 A1
20080177253 Boehringer et al. Jul 2008 A1
20080243096 Svedman et al. Oct 2008 A1
20080275409 Kane et al. Nov 2008 A1
20080287973 Aster et al. Nov 2008 A1
20080306456 Riesinger Dec 2008 A1
20090005716 Abuzaina et al. Jan 2009 A1
20090005744 Karpowicz et al. Jan 2009 A1
20090018578 Wilke et al. Jan 2009 A1
20090018579 Wilke et al. Jan 2009 A1
20090043268 Eddy et al. Feb 2009 A1
20090069760 Finklestein Mar 2009 A1
20090069904 Picha Mar 2009 A1
20090093550 Rolfes et al. Apr 2009 A1
20090099519 Kaplan Apr 2009 A1
20090105670 Bentley et al. Apr 2009 A1
20090131888 Joshi May 2009 A1
20090137973 Karpowicz et al. May 2009 A1
20090204423 Degheest et al. Aug 2009 A1
20090227938 Fasching et al. Sep 2009 A1
20090227969 Jaeb et al. Sep 2009 A1
20090246238 Gorman et al. Oct 2009 A1
20090259203 Hu et al. Oct 2009 A1
20090299255 Kazala, Jr. et al. Dec 2009 A1
20090299256 Barta et al. Dec 2009 A1
20090299303 Seegert Dec 2009 A1
20090299307 Barta et al. Dec 2009 A1
20090299341 Kazala, Jr. et al. Dec 2009 A1
20090299342 Cavanaugh, II et al. Dec 2009 A1
20090312685 Olsen et al. Dec 2009 A1
20100022972 Lina et al. Jan 2010 A1
20100022990 Karpowicz et al. Jan 2010 A1
20100028407 Del et al. Feb 2010 A1
20100030132 Niezgoda et al. Feb 2010 A1
20100036333 Schenk, III Feb 2010 A1
20100047324 Fritz et al. Feb 2010 A1
20100081983 Zocher et al. Apr 2010 A1
20100087854 Stopek et al. Apr 2010 A1
20100100022 Greener et al. Apr 2010 A1
20100100063 Joshi et al. Apr 2010 A1
20100106106 Heaton et al. Apr 2010 A1
20100106184 Coward et al. Apr 2010 A1
20100106188 Heaton et al. Apr 2010 A1
20100121286 Locke et al. May 2010 A1
20100121287 Smith et al. May 2010 A1
20100125233 Edward May 2010 A1
20100137775 Hu et al. Jun 2010 A1
20100137890 Martinez et al. Jun 2010 A1
20100150991 Bernstein Jun 2010 A1
20100160874 Robinson et al. Jun 2010 A1
20100160876 Robinson et al. Jun 2010 A1
20100160901 Hu et al. Jun 2010 A1
20100179515 Swain et al. Jul 2010 A1
20100198128 Turnlund et al. Aug 2010 A1
20100211030 Turner et al. Aug 2010 A1
20100256672 Weinberg et al. Oct 2010 A1
20100262092 Hartwell Oct 2010 A1
20100262106 Hartwell Oct 2010 A1
20100262126 Hu et al. Oct 2010 A1
20100280468 Haggstrom et al. Nov 2010 A1
20100292717 Petter-Puchner et al. Nov 2010 A1
20100298866 Fischvogt Nov 2010 A1
20100305490 Coulthard et al. Dec 2010 A1
20100312159 Aali et al. Dec 2010 A1
20100318046 Boehringer et al. Dec 2010 A1
20110004173 Hu et al. Jan 2011 A1
20110009838 Greener Jan 2011 A1
20110015594 Hu et al. Jan 2011 A1
20110015595 Robinson et al. Jan 2011 A1
20110021965 Karp et al. Jan 2011 A1
20110022082 Burke et al. Jan 2011 A1
20110054283 Shuler Mar 2011 A1
20110054365 Greener Mar 2011 A1
20110059291 Boyce et al. Mar 2011 A1
20110060204 Weston Mar 2011 A1
20110066096 Svedman Mar 2011 A1
20110077605 Karpowicz et al. Mar 2011 A1
20110082480 Viola Apr 2011 A1
20110105963 Hu et al. May 2011 A1
20110106026 Wu et al. May 2011 A1
20110110996 Schoenberger et al. May 2011 A1
20110112458 Holm et al. May 2011 A1
20110113559 Dodd May 2011 A1
20110130774 Criscuolo et al. Jun 2011 A1
20110152800 Eckstein et al. Jun 2011 A1
20110172760 Anderson Jul 2011 A1
20110178451 Robinson Jul 2011 A1
20110196420 Ebner Aug 2011 A1
20110213287 Lattimore et al. Sep 2011 A1
20110213319 Blott et al. Sep 2011 A1
20110224631 Simmons et al. Sep 2011 A1
20110224632 Zimnitsky et al. Sep 2011 A1
20110224634 Locke et al. Sep 2011 A1
20110236460 Stopek et al. Sep 2011 A1
20110238026 Zhang et al. Sep 2011 A1
20110238095 Browning Sep 2011 A1
20110238110 Wilke et al. Sep 2011 A1
20110245682 Robinson et al. Oct 2011 A1
20110245788 Marquez Canada Oct 2011 A1
20110264138 Avelar et al. Oct 2011 A1
20110270201 Bubb et al. Nov 2011 A1
20110270301 Cornet et al. Nov 2011 A1
20110275964 Greener Nov 2011 A1
20110282136 Browning Nov 2011 A1
20110282309 Adie et al. Nov 2011 A1
20110282310 Boehringer et al. Nov 2011 A1
20110305736 Wieland et al. Dec 2011 A1
20110313374 Lockwood et al. Dec 2011 A1
20110319804 Greener Dec 2011 A1
20120004631 Hartwell Jan 2012 A9
20120010637 Stopek et al. Jan 2012 A1
20120016321 Wu et al. Jan 2012 A1
20120016322 Coulthard et al. Jan 2012 A1
20120029449 Khosrowshahi Feb 2012 A1
20120029455 Perez-Foullerat et al. Feb 2012 A1
20120035560 Eddy et al. Feb 2012 A1
20120041402 Greener Feb 2012 A1
20120059399 Hoke et al. Mar 2012 A1
20120059412 Fleischmann Mar 2012 A1
20120065664 Avitable et al. Mar 2012 A1
20120071841 Bengtson Mar 2012 A1
20120073736 O'Connor et al. Mar 2012 A1
20120083755 Lina et al. Apr 2012 A1
20120095426 Visscher et al. Apr 2012 A1
20120109188 Viola May 2012 A1
20120121556 Fraser et al. May 2012 A1
20120123358 Hall et al. May 2012 A1
20120130327 Marquez May 2012 A1
20120136326 Croizat et al. May 2012 A1
20120136328 Johannison et al. May 2012 A1
20120143113 Robinson et al. Jun 2012 A1
20120143158 Yang et al. Jun 2012 A1
20120144989 Du et al. Jun 2012 A1
20120150078 Chen et al. Jun 2012 A1
20120150133 Heaton et al. Jun 2012 A1
20120157942 Weston Jun 2012 A1
20120165764 Allen et al. Jun 2012 A1
20120172778 Rastegar et al. Jul 2012 A1
20120172926 Hotter Jul 2012 A1
20120191054 Kazala, Jr. et al. Jul 2012 A1
20120191132 Sargeant Jul 2012 A1
20120197415 Montanari et al. Aug 2012 A1
20120203189 Barta et al. Aug 2012 A1
20120209226 Simmons et al. Aug 2012 A1
20120209227 Dunn Aug 2012 A1
20120220968 Confalone et al. Aug 2012 A1
20120222687 Czajka, Jr. et al. Sep 2012 A1
20120238931 Rastegar et al. Sep 2012 A1
20120253302 Corley Oct 2012 A1
20120277773 Sargeant et al. Nov 2012 A1
20120302440 Theliander et al. Nov 2012 A1
20130012891 Gross et al. Jan 2013 A1
20130023842 Song Jan 2013 A1
20130066365 Belson et al. Mar 2013 A1
20130096518 Hall et al. Apr 2013 A1
20130110058 Adie et al. May 2013 A1
20130110066 Sharma May 2013 A1
20130131564 Locke et al. May 2013 A1
20130138054 Fleischmann May 2013 A1
20130150813 Gordon et al. Jun 2013 A1
20130150814 Buan Jun 2013 A1
20130190705 Vess et al. Jul 2013 A1
20130197457 Kazala, Jr. et al. Aug 2013 A1
20130204213 Heagle et al. Aug 2013 A1
20130245527 Croizat et al. Sep 2013 A1
20130253401 Locke et al. Sep 2013 A1
20130274717 Dunn Oct 2013 A1
20130310781 Phillips et al. Nov 2013 A1
20130317465 Seegert Nov 2013 A1
20130325142 Hunter et al. Dec 2013 A1
20130331757 Belson Dec 2013 A1
20140066868 Freedman et al. Mar 2014 A1
20140068914 Coward et al. Mar 2014 A1
20140088455 Christensen et al. Mar 2014 A1
20140094730 Greener et al. Apr 2014 A1
20140109560 Ilievski et al. Apr 2014 A1
20140163415 Zaiken et al. Jun 2014 A1
20140180225 Dunn Jun 2014 A1
20140180229 Fuller et al. Jun 2014 A1
20140194836 Kazala, Jr. et al. Jul 2014 A1
20140194837 Robinson et al. Jul 2014 A1
20140195004 Engqvist et al. Jul 2014 A9
20140213994 Hardman et al. Jul 2014 A1
20140228789 Wilkes et al. Aug 2014 A1
20140249495 Mumby et al. Sep 2014 A1
20140316359 Collinson et al. Oct 2014 A1
20140336602 Karpowicz et al. Nov 2014 A1
20140343517 Jameson Nov 2014 A1
20140343518 Riesinger Nov 2014 A1
20150000018 Brandt Jan 2015 A1
20150005722 Hu et al. Jan 2015 A1
20150025484 Simmons et al. Jan 2015 A1
20150030806 Fink Jan 2015 A1
20150057762 Harms et al. Feb 2015 A1
20150065805 Edmondson et al. Mar 2015 A1
20150065968 Sealy et al. Mar 2015 A1
20150075697 Gildersleeve Mar 2015 A1
20150080947 Greener Mar 2015 A1
20150100008 Chatterjee Apr 2015 A1
20150112290 Dunn Apr 2015 A1
20150112311 Hammond et al. Apr 2015 A1
20150119837 Thompson, Jr. et al. Apr 2015 A1
20150119865 Barta et al. Apr 2015 A1
20150148760 Dodd et al. May 2015 A1
20150150729 Dagger et al. Jun 2015 A1
20150157758 Blücher et al. Jun 2015 A1
20150159066 Hartwell et al. Jun 2015 A1
20150164174 West Jun 2015 A1
20150174304 Askem et al. Jun 2015 A1
20150190288 Dunn et al. Jul 2015 A1
20150196431 Dunn et al. Jul 2015 A1
20150216732 Hartwell et al. Aug 2015 A1
20150320434 Ingram et al. Nov 2015 A1
20150320602 Locke et al. Nov 2015 A1
20150374561 Hubbard, Jr. et al. Dec 2015 A1
20160022885 Dunn et al. Jan 2016 A1
20160030646 Hartwell et al. Feb 2016 A1
20160067939 Liebe et al. Mar 2016 A1
20160144085 Melin et al. May 2016 A1
20160166744 Hartwell Jun 2016 A1
20160184496 Jaecklein et al. Jun 2016 A1
20160235897 Boynton et al. Aug 2016 A1
20160354086 Dunn Dec 2016 A1
20170007462 Hartwell et al. Jan 2017 A1
20170007751 Hartwell et al. Jan 2017 A1
20170065751 Toth et al. Mar 2017 A1
20170156611 Burnett et al. Jun 2017 A1
20170165116 Dunn Jun 2017 A1
20170281838 Dunn Oct 2017 A1
20180140465 Dunn et al. May 2018 A1
20190105202 Dunn et al. Apr 2019 A1
20190231944 Dunn et al. Aug 2019 A1
20190262182 Collinson et al. Aug 2019 A1
20200038023 Dunn Feb 2020 A1
20200188564 Dunn Jun 2020 A1
20200268562 Dunn Aug 2020 A1
20200330661 Canner et al. Oct 2020 A1
Foreign Referenced Citations (184)
Number Date Country
2012261793 Nov 2014 AU
2013206230 May 2016 AU
2747743 Jul 2010 CA
2701233 Nov 2010 CA
1438904 Aug 2003 CN
101112326 Jan 2008 CN
101123930 Feb 2008 CN
101208115 Jun 2008 CN
101257938 Sep 2008 CN
101588836 Nov 2009 CN
101744688 Jun 2010 CN
201519362 Jul 2010 CN
102038575 May 2011 CN
102046117 May 2011 CN
102196830 Sep 2011 CN
102256637 Nov 2011 CN
102781380 Nov 2012 CN
202568632 Dec 2012 CN
103071197 May 2013 CN
103405846 Nov 2013 CN
103501709 Jan 2014 CN
203408163 Jan 2014 CN
104736110 Jun 2015 CN
104768474 Jul 2015 CN
104812343 Jul 2015 CN
2949920 Mar 1981 DE
102005007016 Aug 2006 DE
102012001752 Aug 2013 DE
1320342 Jun 2003 EP
2094211 Sep 2009 EP
2279016 Feb 2011 EP
2341955 Jul 2011 EP
2366721 Sep 2011 EP
2367517 Sep 2011 EP
2368523 Sep 2011 EP
2404571 Jan 2012 EP
2404626 Jan 2012 EP
2529767 Dec 2012 EP
2547375 Jan 2013 EP
2563421 Mar 2013 EP
2567682 Mar 2013 EP
2567717 Mar 2013 EP
2594299 May 2013 EP
2601984 Jun 2013 EP
2623137 Aug 2013 EP
2759265 Jul 2014 EP
2829287 Jan 2015 EP
2872085 May 2015 EP
3225261 Oct 2017 EP
2389794 Dec 2003 GB
2378392 Jun 2004 GB
2423019 Aug 2006 GB
2489947 Oct 2012 GB
2496310 May 2013 GB
2496310 May 2013 GB
20140129 Mar 2016 IE
S6257560 Mar 1987 JP
H0341952 Feb 1991 JP
H09-503923 Apr 1997 JP
2006528038 Dec 2006 JP
2007-505678 Mar 2007 JP
2007-531567 Nov 2007 JP
2008-529618 Aug 2008 JP
2009525087 Jul 2009 JP
2009-536851 Oct 2009 JP
2010-526597 Aug 2010 JP
2011-500170 Jan 2011 JP
2011521 740 Jul 2011 JP
2011-523575 Aug 2011 JP
2011-526798 Oct 2011 JP
2012-504460 Feb 2012 JP
2012-105840 Jun 2012 JP
2012-513826 Jun 2012 JP
2012529974 Nov 2012 JP
2013-526938 Jun 2013 JP
2014168573 Sep 2014 JP
1818103 May 1993 RU
62504 Apr 2007 RU
WO-199420041 Sep 1994 WO
WO-200059424 Oct 2000 WO
WO-200134223 May 2001 WO
WO-2001085248 Nov 2001 WO
WO-200189392 Nov 2001 WO
WO-0205737 Jan 2002 WO
WO-03003948 Jan 2003 WO
WO-03049598 Jun 2003 WO
WO-2004018020 Mar 2004 WO
WO-2004037334 May 2004 WO
WO-2005046761 May 2005 WO
WO-2005105174 Nov 2005 WO
WO 2006041496 Apr 2006 WO
WO-2006046060 May 2006 WO
WO-2006087021 Aug 2006 WO
WO-2006100053 Sep 2006 WO
WO-2007030601 Mar 2007 WO
WO-2007120138 Oct 2007 WO
WO-2007133618 Nov 2007 WO
WO-2008005532 Jan 2008 WO
WO 2008027449 Mar 2008 WO
WO-2008039223 Apr 2008 WO
WO-2008039839 Apr 2008 WO
WO-2008064502 Jun 2008 WO
WO-2008091521 Jul 2008 WO
WO-2008104609 Sep 2008 WO
WO-2009019495 Feb 2009 WO
WO-2009071926 Jun 2009 WO
WO-2009071933 Jun 2009 WO
WO-2009093116 Jul 2009 WO
WO-2009112848 Sep 2009 WO
WO-2009114624 Sep 2009 WO
WO-2009112062 Sep 2009 WO
WO-2009158125 Dec 2009 WO
WO-2009158132 Dec 2009 WO
WO-2009156709 Dec 2009 WO
WO-2010033725 Mar 2010 WO
WO-2010051073 May 2010 WO
WO-2010059612 May 2010 WO
WO-2010075178 Jul 2010 WO
WO-2010075180 Jul 2010 WO
WO-2010078349 Jul 2010 WO
WO-2010079359 Jul 2010 WO
WO-2010092334 Aug 2010 WO
WO-2010147535 Dec 2010 WO
WO-2011023384 Mar 2011 WO
WO-2011091169 Jul 2011 WO
WO-2011106722 Sep 2011 WO
WO-2011115908 Sep 2011 WO
WO-2011116691 Sep 2011 WO
WO-2011135284 Nov 2011 WO
WO-2011135286 Nov 2011 WO
WO-2011135287 Nov 2011 WO
WO-2011144888 Nov 2011 WO
WO-2011137230 Nov 2011 WO
WO-2012021553 Feb 2012 WO
WO-2012038727 Mar 2012 WO
WO-2012069793 May 2012 WO
WO 2012082716 Jun 2012 WO
WO-2012087376 Jun 2012 WO
WO-2012082876 Jun 2012 WO
WO-2012106590 Aug 2012 WO
WO-2012112204 Aug 2012 WO
WO-2012136707 Oct 2012 WO
WO-2012142473 Oct 2012 WO
WO-2012156655 Nov 2012 WO
WO-2013007973 Jan 2013 WO
WO-2013012381 Jan 2013 WO
WO-2013043258 Mar 2013 WO
WO-2013074829 May 2013 WO
WO-2013076450 May 2013 WO
WO-2013071243 May 2013 WO
WO-2013079447 Jun 2013 WO
WO-2013079947 Jun 2013 WO
WO-2013136181 Sep 2013 WO
WO-2013175309 Nov 2013 WO
WO-2013175310 Nov 2013 WO
WO-2014013348 Jan 2014 WO
WO-2014014842 Jan 2014 WO
WO-2014014871 Jan 2014 WO
WO-2014014922 Jan 2014 WO
WO-2014024048 Feb 2014 WO
WO-2014140578 Sep 2014 WO
WO-2014165275 Oct 2014 WO
WO-2014158526 Oct 2014 WO
WO-2014178945 Nov 2014 WO
WO-2014194786 Dec 2014 WO
WO-2015008054 Jan 2015 WO
WO-2015061352 Apr 2015 WO
WO-2015109359 Jul 2015 WO
WO-2015110409 Jul 2015 WO
WO-2015110410 Jul 2015 WO
WO-2015169637 Nov 2015 WO
WO-2015172108 Nov 2015 WO
WO-2015193257 Dec 2015 WO
WO-2016018448 Feb 2016 WO
WO-2016176513 Nov 2016 WO
WO-2016179245 Nov 2016 WO
WO-2016184913 Nov 2016 WO
WO-2017063036 Apr 2017 WO
WO-2017106576 Jun 2017 WO
WO-2018038665 Mar 2018 WO
WO-2018041805 Mar 2018 WO
WO-2018044944 Mar 2018 WO
WO-2018044949 Mar 2018 WO
WO-2018237206 Dec 2018 WO
Non-Patent Literature Citations (15)
Entry
“Definition of Oculiform,” Webster's Revised Unabridged Dictionary, accessed from The Free Dictionary on May 30, 2018 from URL: https://www.thefreedictionary.com/Oculiform, 1913, 1 page.
International Preliminary Reporton Patentability for Application No. PCT/IB2013/001555, dated Nov. 25, 2014, 5 pages.
International Search Report and Written Opinion for Application No. PCT/IB2013/001555, dated Sep. 3, 2013, 7 pages.
Kapischke M., et al., “Self-Fixating Mesh for the Lichtenstein Procedure—a Prestudy,” Langenbecks Arch Surg, 2010, vol. 395, pp. 317-322.
“Definition of 3D Printer,” American Heritage Dictionary of the English Language, Fifth Edition, accessed on Feb. 22, 2018 from URL: https://www.thefreedictionary.com, 2016, 1 page.
“Definition of Adhere,” The Free Dictionary, accessed on Mar. 23, 2017 from http://www.thefreedictionary.com/adhere, 6 pages.
“Definition of Throughout,” Merriam-Webster Dictionary, accessed on Aug. 29, 2017 from https://www.merriam-webster.com/dictionary/throughout, 11 pages.
Bengezi et al., Elevation as a treatment for fasciotomy wound closure. Can J Plast Surg. 2013 Fall;21(3):192-4.
Epstein et al., Lipoabdominoplasty Without Drains or Progressive Tension Sutures: An Analysis of 100 Consecutive Patients. Aesthetic Surgery Journal. Apr. 2015;35(4):434-440.
Hougaard et al., The open abdomen: temporary closure with a modified negative pressure therapy technique. Int Wound J. Jun. 2014;11 Suppl 1:13-6.
Jauregui et al., Fasciotomy closure techniques. J Orthop Surg (Hong Kong). Jan. 2017;25(1):2309499016684724. 8 pages.
Macias et al., Decrease in Seroma Rate After Adopting Progressive Tension Sutures Without Drains: A Single Surgery Center Experience of 451 Abdominoplasties over 7 Years. Aesthetic Surgery Journal. Mar. 2016;36(9):1029-1035.
Pollock et al., Progressive Tension Sutures in Abdominoplasty: A Review of 597 Consecutive Cases. Aesthetic Surgery Journal. Aug. 2012;32(6):729-742.
Quaba et al., The no-drain, no-quilt abdominoplasty: a single-surgeon series of 271 patients. Plast Reconstr Surg. Mar. 2015;135(3):751-60.
Rothenberg et al., Emerging Insights On Closed Incision NPWT And Transmetatarsal Amputations. http://www.podiatrytoday.com/emerging-insights-closed-incision-npwt-and-transmetatarsal-amputations. Apr. 2015;28(4):1-5.
Related Publications (1)
Number Date Country
20190231599 A1 Aug 2019 US
Provisional Applications (2)
Number Date Country
61782270 Mar 2013 US
61651483 May 2012 US
Continuations (1)
Number Date Country
Parent 14403163 US
Child 16177146 US